Randomized control trial of transarterial chemoembolization with miriplatin-lipiodol suspension or drug eluting bead with doxorubicin for hepatocellular carcinoma
Not Applicable
- Conditions
- hepatocellular carcinoma
- Registration Number
- JPRN-UMIN000013204
- Lead Sponsor
- Department of Gastroenterology and Hepatology, Nagoya University Graduate School of Medicine, Aichi, Japan
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Complete: follow-up complete
- Sex
- All
- Target Recruitment
- 56
Inclusion Criteria
Not provided
Exclusion Criteria
1)Having metastasis. 2)Having vascular invasion. 3)Having vascular anormality or AP shunt. 4)Having previous treatment with miriplatin or DC bead. 5)Having previous treatment with sorafenib. 6)Having severe ascites or pleural effusion. 7)Considered as HCC refractory for TACE. 8)Having allergy of contrast agent. 9)Having severe renal failure. 10)Having severe cardiac disease. 11)Having other cancer. 12)Having hemorrhagic varix. 13)Having severe mental disorder. 14)Having severe drug allergy. 15)Having possibility of pregnant or nursing. 16)Deemed inappropriate to perform the study by the physician.
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Anti-tumor response
- Secondary Outcome Measures
Name Time Method Progression free survival